OPK

OPKO Health, Inc. - Q1 2011 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2011. OPKO Health, Inc. is a multi-national pharmaceutical and diagnostics company focused on neurological disorders, infectious diseases, oncology, and ophthalmologic diseases. The company operates through two primary segments: pharmaceutical (including emerging markets in Chile and Mexico) and instrumentation (ophthalmic devices). As of May 1, 2011, the company had 285,060,055 shares of common stock outstanding.

Key Financial Metrics

Note: The company reported a net loss per share of $(0.02) for both periods.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 9.2% to $8.6 million, driven primarily by growth in the pharmaceutical segment (Chile and Mexico operations). Conversely, instrumentation revenue declined due to decreased international demand for OCT/SLO products.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses rose to $5.6 million from $4.2 million, attributed to increased warehousing costs in Chile, higher equity-based compensation ($1.4 million vs. $1.0 million), and a full quarter of expenses for Mexican operations.
• Acquisition Activity: In January 2011, OPKO acquired CURNA, Inc. for approximately $10.6 million (cash and liabilities), adding technology for drug discovery in cancer and metabolic disorders. This resulted in increased intangible assets and amortization expenses.
• Capital Raise: In March 2011, the company completed a public offering of 29.4 million shares, raising approximately $104.8 million in net proceeds. This significantly improved liquidity compared to the prior year.
• Investment Losses: Loss from investments in investees increased to $423,000 from $231,000, reflecting equity method accounting adjustments for entities like Sorrento, Cocrystal, and Fabrus.

Outlook, Risks, and Management Commentary

• Liquidity Position: Management states that cash, cash equivalents, and marketable securities totaling approximately $107.9 million, combined with available credit lines, are sufficient to fund operations for more than 12 months.
• Future Funding Needs: The company expects to incur substantial operating losses for the foreseeable future due to R&D activities and the expansion of sales and marketing infrastructure. Additional capital may be required for clinical trials and acquisitions.
• Key Risks:
  • History of operating losses with no expectation of near-term profitability.
  • Technologies are in early stages of development and unproven.
  • Dependence on third-party manufacturers and collaborators (e.g., TESARO for rolapitant).
  • Regulatory approval uncertainties for product candidates.
  • Foreign currency exchange rate fluctuations affecting Chilean and Mexican operations.
• Subsequent Events: The company initiated the redemption of Series A Preferred Stock in May 2011, with a potential cash payment of approximately $2.1 million if shares are not converted.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $107.9 million cash position against the projected R&D and SG&A burn rate, given the history of losses.
• Acquisition Integration: Assess the progress of the CURNA acquisition and the likelihood of achieving the contingent consideration milestones.
• Revenue Concentration: Note that one customer represented 12% of total revenue and 30% of accounts receivable in Q1 2011.
• Related Party Transactions: Review the $12 million line of credit with the Frost Group (affiliated with the CEO) and the terms of the 11% interest rate.
• Preferred Stock Redemption: Confirm the final outcome of the Series A Preferred Stock redemption and its impact on cash flow.